查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1818191

CT-NG 分子检测市场报告：2031 年趋势、预测与竞争分析

CT-NG Molecular Test Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球新生儿疑似（CT-NG）分子检测市场前景光明，诊断实验室和医院诊所都蕴藏着巨大的机会。预计2025年至2031年期间，全球新生儿疑似（CT-NG）分子检测市场的复合年增长率将达到8.3%。该市场的主要驱动力在于对照护现场和家用检测的需求日益增长，以及诊断工具的技术进步。

  • Lucintel 预测，对于常规检测、筛检和照护现场至关重要的检测试剂和套件将在预测期内实现高速成长。
  • 从应用角度来看，在广泛的测试和诊断中发挥核心作用的医院和诊所预计将实现高成长。
  • 按地区划分，预计北美将在预测期内实现最高成长。

CT-NG分子检测市场的新趋势

随着CT-NG分子检测市场的不断发展，一些趋势正在涌现，这些趋势反映了医疗技术、监管格局和市场动态的广泛变化。这些趋势正在重塑诊断方式，提高可及性，并提升检测的速度和准确性。

  • 家用检测套组的兴起：披衣菌感染和淋病的家用检测套组越来越受欢迎，尤其是在美国和欧洲等地区。这些检测套组既私密又便捷，对于那些可能因污名化和其他障碍而不愿去临床就诊的人来说，也更容易获得。分子诊断技术的进步使得在实验室外进行精确检测成为可能，这也进一步推动了这一趋势。随着越来越多的检测可以在家中进行，预计整体市场将会扩大，这主要得益于消费者对便捷私密诊断方案的需求。
  • 照护现场检测 (POC) 整合：照护现场(POC) 整合是 CT-NG 分子检测市场的关键趋势。这些可携式、快速且易于使用的设备可在诊所、行动医疗单位和其他医疗机构进行快速检测。即时检测可最大限度地缩短等待结果的时间，并改善患者管理和护理。这一趋势将对农村和服务欠缺地区产生特别显着的影响，因为这些地区可能无法获得传统实验室，有助于在医疗资源有限的地区推广分子检测。
  • 行动医疗(行动健康医疗) 与远端医疗的整合：行动医疗(M Health) 和远端医疗正在透过提高检测的可近性来重塑 CT-NG 分子检测市场。随着智慧型手机的广泛普及，越来越多的诊断平台正在与行动装置集成，从而实现自我检测、远端咨询，甚至线上处方服务。这一趋势在中国和印度等国家尤其明显，因为行动技术正成为主要的通讯和医疗服务取得方式。医疗健康与远端医疗的结合提高了检测的便利性，加快了结果的获取速度，并提供了远距医疗服务。
  • 预防性医疗保健日益受到重视：预防性医疗保健的关注推动了对分子诊断（包括CT-NG检测）的需求。世界各国政府和组织都认识到早期发现和治疗性行为感染传染病的重要性。作为更广泛的公共卫生策略的一部分，许多国家正在实施定期筛检，尤其针对青少年和年轻人等高风险族群。定期筛检的推动，加上分子检测的普及，预计将推动市场进一步成长。
  • 个人化医疗与诊断精准化：随着个人化医疗的不断发展，对能够提供个人化治疗方案的高精度诊断检测的需求日益增长。 CT和NG等分子检测因其高灵敏度和特异性而尤其契合这一趋势。将分子诊断纳入精准医疗框架将改善治疗效果并减少感染疾病的传播。个人化医疗趋势在美国、日本和德国等新兴市场尤其明显，这些市场更重视个别病患的需求。

各种新兴趋势正在重塑CT-NG分子检测市场，包括家用检测套组、照护现场以及医疗与远端医疗的融合。这些趋势正在提高可近性、准确性和便利性，并将继续推动市场扩张，尤其是在医疗资源匮乏和偏远地区。随着全球医疗保健系统更加重视预防措施和个人化医疗，分子诊断的需求预计将大幅成长。

CT-NG分子检测市场的最新趋势

CT-NG分子检测市场正受到近期多种趋势的影响，这些趋势受到技术进步、监管部门核准以及医疗保健管道不断扩大的推动。以下是推动市场成长和发展的五个关键发展：

  • FDA核准快速分子检测：FDA 最近核准了几种针对披衣菌感染和淋病的快速分子检测，对披衣菌感染-淋病 (CT-NG) 分子检测市场产生了重大影响。这些检测能够快速获得结果，减少患者和医疗保健提供者的等待时间。快速结果对于公共卫生回应和性传染感染 (STI) 的有效管理尤其重要，这促使人们越来越多地采用分子检测，而非传统的培养和抗原检测等方法。
  • 扩大就地检验：披衣菌感染和淋病的即时检测设备正在临床和社区医疗机构中迅速普及。这些设备能够提供快速且准确的结果，对于改善农村和资源匮乏地区的性传染感染管理至关重要。扩大即时检测满足了人们对便利、经济、快速诊断的需求。这项发展对于提高性传染感染筛检率和防止感染传播至关重要。
  • 行动和家用检测解决方案：针对性传播感染 (CT) 和鼻咽癌 (NG) 的行动和家用检测解决方案正日益普及，尤其是在美国和欧洲等已开发国家。这些解决方案允许个人自行进行检测，并将结果发送给医疗保健提供者进行后续追踪。家用检测套组的日益普及反映了人们对性传染感染检测的便利性、隐私性和可及性日益增长的需求，这进一步推动了性传染感染-鼻咽癌分子检测市场的成长。
  • PCR技术的进步：聚合酵素链锁反应(PCR) 技术不断发展，在检测披衣菌感染和淋病感染方面提高了灵敏度、准确性和效率。这些进步促进了更有效、更可靠的分子诊断检测方法的发展。检测低水平感染的能力有望提高早期检出率，并推动基于PCR的分子检测在临床实践中的应用。
  • 开发中地区诊断基础设施的成长：印度和中国等新兴市场不断扩展的诊断基础设施正在支持CT-NG分子检测市场的成长。政府和私营部门不断增加的投资正在改善先进分子检测技术的可近性。这一发展对于应对这些地区性传播感染日益严重的问题尤其重要，它使更多人能够获得早期和准确的检测，从而促进市场成长。

监管部门的核准、检测技术的进步以及诊断基础设施的不断扩展等最新进展正在改变CT-NG分子检测市场。这些发展改善了获得准确快速诊断的途径，使检测更加普及，并惠及更广泛的人群，预计将推动全球市场的成长。

目录

第一章执行摘要

第二章 市场概况

  • 背景和分类
  • 供应链

第三章：市场趋势及预测分析

  • 宏观经济趋势与预测
  • 产业驱动力与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

4.按类型分類的全球 CT-NG 分子检测市场

  • 概述
  • 按类型进行吸引力分析
  • 检测试剂套件：趋势与预测（2019-2031）
  • 分析仪：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

5. 全球 CT-NG 分子检测市场（依应用）

  • 概述
  • 按用途进行吸引力分析
  • 诊断实验室：趋势与预测（2019-2031）
  • 医院与诊所：趋势与预测（2019-2031）
  • 其他：趋势与预测（2019-2031）

第六章 区域分析

  • 概述
  • 区域CT-NG分子检测市场

7.北美CT-NG分子检测市场

  • 概述
  • 美国CT-NG分子检测市场
  • 墨西哥的CT-NG分子检测市场
  • 加拿大CT-NG分子检测市场

8.欧洲CT-NG分子侦测市场

  • 概述
  • 德国CT-NG分子检测市场
  • 法国CT-NG分子检测市场
  • 西班牙CT-NG分子检测市场
  • 义大利CT-NG分子检测市场
  • 英国CT-NG分子检测市场

9.亚太CT-NG分子检测市场

  • 概述
  • 日本CT-NG分子检测市场
  • 印度CT-NG分子检测市场
  • 中国CT-NG分子检测市场
  • 韩国CT-NG分子检测市场
  • 印尼CT-NG分子检测市场

10. 其他地区 CT-NG 分子检测市场

  • 概述
  • 中东CT-NG分子检测市场
  • 南美洲CT-NG分子检测市场
  • 非洲CT-NG分子检测市场

第11章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析
    • 竞争对手之间的竞争
    • 买方的议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 新进入者的威胁
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
    • 按类型分類的成长机会
    • 按应用分類的成长机会
  • 全球 CT-NG 分子检测市场的新趋势
  • 战略分析
    • 新产品开发
    • 认证和许可
    • 合併、收购、协议、合作和合资企业

第十三章 价值链主要企业的公司简介

  • 竞争分析
  • Roche
  • Hologic
  • Thermo Fisher Scientific
  • Abbott
  • PerkinElmer
  • Qiagen
  • Siemens Healthineers
  • Danaher
  • BD
  • Bio-Rad

第十四章 附录

  • 图表目录
  • 表格一览
  • 调查方法
  • 免责声明
  • 版权
  • 简称和技术单位
  • 关于我们
  • 联络处

The future of the global CT-NG molecular test market looks promising with opportunities in the diagnostic laboratories and hospitals & clinics markets. The global CT-NG molecular test market is expected to grow with a CAGR of 8.3% from 2025 to 2031. The major drivers for this market are the increasing demand for point-of-care and home testing and the technological advancements in diagnostic tools.

  • Lucintel forecasts that, within the type category, assays & kits is expected to witness higher growth over the forecast period due to they are essential in routine testing, screening, and point-of-care diagnostics.
  • Within the application category, hospitals & clinics is expected to witness the higher growth due to central role in providing widespread testing and diagnosis.
  • In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the CT-NG Molecular Test Market

As the CT-NG molecular test market continues to evolve, several trends are emerging that reflect broader shifts in healthcare technology, regulatory landscapes, and market dynamics. These trends are reshaping how diagnostics are delivered, improving accessibility, and enhancing the speed and accuracy of testing.

  • Rise of At-Home Testing Kits: At-home testing kits for Chlamydia and Gonorrhea are gaining popularity, especially in regions like the U.S. and Europe. These kits offer privacy, convenience, and greater accessibility for individuals who may otherwise avoid clinical settings due to stigma or other barriers. The trend is supported by advancements in molecular diagnostic technology that make accurate testing possible outside of laboratories. As more tests are available for home use, the overall market is expected to grow, driven by consumer demand for easy and private diagnostic options.
  • Integration of Point-of-Care (POC) Testing: The integration of point-of-care (POC) testing is an important trend in the CT-NG molecular test market. These portable, fast, and easy-to-use devices allow for rapid testing at clinics, mobile units, and other healthcare settings. POC testing minimizes waiting times for results, improving patient management and care. This trend is particularly impactful in rural and underserved areas where access to traditional laboratories may be limited, helping to drive the adoption of molecular tests in regions with limited healthcare resources.
  • Mobile Health (M Health) and Telemedicine Integration: Mobile health (M Health) and telemedicine are reshaping the CT-NG molecular test market by improving accessibility to testing. With increasing smartphone penetration, more diagnostic platforms are integrating with mobile devices, allowing for self-testing, remote consultation, and even online prescription services. This trend is particularly relevant in countries like China and India, where mobile technology is becoming a primary mode of communication and healthcare access. The combination of health with telemedicine increases the convenience of getting tested, providing faster results and remote healthcare services.
  • Increased Focus on Preventive Healthcare: The focus on preventive healthcare is driving the demand for molecular diagnostics, including CT-NG tests. Governments and organizations worldwide are recognizing the importance of early detection and treatment of sexually transmitted infections. As part of broader public health strategies, many countries are implementing regular screenings, particularly for high-risk groups such as adolescents and young adults. The promotion of regular screenings, combined with more widespread availability of molecular tests, is expected to push the market toward further growth.
  • Personalized Medicine and Diagnostic Accuracy: As personalized medicine continues to evolve, there is an increasing demand for highly accurate diagnostic tests that provide tailored treatment options. Molecular tests for CT and NG are particularly suited for this trend, as they offer high sensitivity and specificity. The integration of molecular diagnostics into precision medicine frameworks enhances treatment outcomes and reduces the transmission of infections. The trend toward personalized care is especially relevant in developed markets like the U.S., Japan, and Germany, where there is a strong focus on individual patient needs.

The CT-NG molecular test market is being reshaped by a range of emerging trends, including at-home testing kits, point-of-care diagnostics, and the integration of health and telemedicine. These trends are improving accessibility, accuracy, and convenience, which will likely continue to drive market expansion, especially in underserved and remote areas. As healthcare systems worldwide focus more on preventive measures and personalized medicine, the demand for molecular diagnostics is set to grow significantly.

Recent Developments in the CT-NG Molecular Test Market

Several recent developments are shaping the CT-NG molecular test market, driven by advances in technology, regulatory approvals, and expanding healthcare access. Below are five key developments that are contributing to the growth and evolution of the market.

  • FDA Approvals for Rapid Molecular Tests: The FDA has recently approved several rapid molecular tests for Chlamydia and Gonorrhea, which have a significant impact on the CT-NG molecular test market. These tests offer quicker results, reducing waiting times for patients and healthcare providers. The faster turnaround is particularly useful for improving public health responses and managing STIs effectively, thereby driving the adoption of molecular testing over traditional methods like cultures or antigen tests.
  • Expansion of Point-of-Care Testing: Point-of-care testing devices for Chlamydia and Gonorrhea are rapidly expanding in clinical and community healthcare settings. These devices provide quick, accurate results and are crucial for improving STI management in rural or resource-limited areas. The increasing adoption of POC tests is addressing the need for accessible, low-cost, and rapid diagnostics. This development is key to improving STI screening rates and preventing the spread of infections.
  • Mobile and Home Testing Solutions: Mobile and at-home testing solutions for CT and NG are gaining traction, especially in developed countries like the U.S. and Europe. These solutions allow individuals to perform tests privately, with results sent to healthcare providers for follow-up. The increasing availability of home testing kits reflects the growing demand for convenience, privacy, and accessibility in STI testing, further driving the market growth for CT-NG molecular tests.
  • Advancements in PCR Technology: Polymerase chain reaction (PCR) technology continues to advance, offering increased sensitivity, accuracy, and efficiency in detecting Chlamydia and Gonorrhea infections. These advancements have led to the development of more effective and reliable molecular diagnostic tests. The ability to detect lower levels of infection has improved early detection rates and is expected to drive the adoption of PCR-based molecular tests in clinical settings.
  • Growth of Diagnostic Infrastructure in Developing Regions: The expansion of diagnostic infrastructure in developing regions, such as India and China, is supporting the growth of the CT-NG molecular test market. With increased government and private sector investments, access to advanced molecular testing technologies is improving. This development is particularly important for addressing the rising incidence of STIs in these regions, contributing to the market's growth as more individuals gain access to early and accurate testing.

Recent developments, including regulatory approvals, advancements in testing technology, and the expansion of diagnostic infrastructure, are transforming the CT-NG molecular test market. These developments are improving access to accurate and rapid diagnostics, making testing more widely available and accessible to diverse populations. This is expected to drive market growth globally.

Strategic Growth Opportunities in the CT-NG Molecular Test Market

The CT-NG molecular test market presents several strategic growth opportunities across different applications. These opportunities are driven by advancements in testing technology, growing healthcare needs, and regulatory support. Below are five key growth opportunities by application.

  • Expansion in Routine STI Screening: There is significant growth potential for CT-NG molecular tests in routine STI screening, particularly among high-risk groups like adolescents and sexually active adults. Regular screenings help identify infections early, leading to faster treatment and reducing transmission rates. This growing demand for routine STI testing presents a major opportunity for molecular diagnostic companies.
  • Telemedicine and Remote Diagnostics: Telemedicine platforms are increasingly integrating CT-NG molecular tests to offer remote diagnosis and treatment options. This is particularly beneficial for underserved populations or those who prefer not to visit healthcare facilities. The rise of telemedicine presents a key growth opportunity for expanding market reach and improving patient outcomes.
  • Integration in Public Health Programs: CT-NG molecular tests are being integrated into public health programs aimed at controlling and reducing the spread of STIs. Governments and health organizations are prioritizing STI screening and prevention, creating opportunities for molecular diagnostics to play a significant role in public health initiatives. This will drive the adoption of molecular tests in national health programs.
  • Growth in Women's Health: The CT-NG molecular test market has significant growth potential in women's health applications, especially in maternal and reproductive healthcare. Chlamydia and Gonorrhea are among the leading causes of infertility and complications in pregnancy. As more focus is placed on reproductive health, the demand for early, accurate testing will increase, opening up growth opportunities for molecular diagnostics in this sector.
  • Point-of-Care (POC) Testing Expansion: The expanding use of point-of-care testing for Chlamydia and Gonorrhea represents a significant opportunity for market growth. These tests are easy to use, offer rapid results, and can be conducted in various settings, from clinics to mobile health units. This growth in POC testing will drive demand for molecular tests across diverse healthcare environments.

These strategic growth opportunities highlight the expanding role of CT-NG molecular tests across various applications, including routine screening, public health initiatives, and women's health. The ongoing integration of molecular diagnostics into diverse healthcare systems is set to significantly enhance market adoption and growth.

CT-NG Molecular Test Market Driver and Challenges

The CT-NG molecular test market is driven by several technological, economic, and regulatory factors, but also faces various challenges. Understanding these drivers and challenges is essential for stakeholders to navigate the market.

The factors responsible for driving the CT-NG molecular test market include:

1. Technological Advancements in Molecular Diagnostics: Ongoing advancements in molecular diagnostic technologies, such as PCR and next-generation sequencing, are enabling more accurate, rapid, and cost-effective tests for Chlamydia and Gonorrhea. These innovations make molecular diagnostics more widely accessible, driving market growth by improving the speed and reliability of test results.

2. Increased Awareness of STIs: Growing awareness of STIs and their long-term health impacts is fueling the demand for CT-NG molecular tests. Public health campaigns and education about the risks of untreated STIs are increasing the adoption of routine testing and preventive measures, expanding the market for molecular diagnostics.

3. Regulatory Support for Molecular Diagnostics: Regulatory agencies, such as the FDA, are increasingly approving molecular diagnostic tests for STIs, making them more accessible to healthcare providers. Supportive regulatory frameworks are encouraging innovation and the availability of new products in the CT-NG molecular test market, contributing to market expansion.

4. Rising Demand for Preventive Healthcare: The global shift towards preventive healthcare is driving the adoption of molecular diagnostic tests like those for Chlamydia and Gonorrhea. Early detection of infections prevents long-term health complications and reduces transmission rates, contributing to the rising demand for molecular tests.

5. Increased Healthcare Investment in Developing Markets: The rising investment in healthcare infrastructure in developing regions like India and China is enabling the adoption of molecular diagnostics. Governments and the private sector are prioritizing investments in diagnostic technologies, which is driving the market for CT-NG molecular tests in these regions.

Challenges in the CT-NG molecular test market are:

1. High Cost of Molecular Testing: The high cost of molecular diagnostic tests remains a significant barrier, particularly in developing countries with limited healthcare budgets. While technological advancements are reducing costs, affordability remains a challenge for widespread adoption in low-resource settings.

2. Competition from Rapid Antigen Tests: Rapid antigen tests, which are cheaper and quicker than molecular tests, continue to compete in the market for STI diagnostics. Although antigen tests are less sensitive, they offer an alternative for fast testing, particularly in resource-limited environments.

3. Limited Access to Diagnostic Infrastructure in Rural Areas: In many rural and underserved areas, the lack of diagnostic infrastructure and trained personnel can hinder the adoption of molecular testing. Expanding access to testing facilities and mobile health services is necessary to overcome this challenge.

The CT-NG molecular test market is influenced by strong drivers such as technological advancements and increasing demand for preventive healthcare, but faces challenges like high costs and competition from alternative tests. As stakeholders address these challenges, the market is likely to see continued growth and innovation.

List of CT-NG Molecular Test Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies CT-NG molecular test companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the CT-NG molecular test companies profiled in this report include-

  • Roche
  • Hologic
  • Thermo Fisher Scientific
  • Abbott
  • PerkinElmer
  • Qiagen
  • Siemens Healthineers
  • Danaher
  • BD
  • Bio-Rad

CT-NG Molecular Test Market by Segment

The study includes a forecast for the global CT-NG molecular test market by type, application, and region.

CT-NG Molecular Test Market by Type [Value from 2019 to 2031]:

  • Assays & Kits
  • Analyzers
  • Others

CT-NG Molecular Test Market by Application [Value from 2019 to 2031]:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others

CT-NG Molecular Test Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the CT-NG Molecular Test Market

The CT-NG molecular test market has been experiencing notable advancements due to the growing need for precise and rapid diagnostics in sexually transmitted infections (STIs), particularly Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). These tests are crucial for early detection, treatment, and prevention of STIs, and have gained significant traction globally due to their high sensitivity and specificity. As healthcare systems in developed and emerging markets embrace more advanced molecular diagnostics, innovations in testing methods, regulatory approvals, and market access are reshaping the CT-NG molecular test landscape across key regions like the United States, China, Germany, India, and Japan.

  • United States: In the U.S., the CT-NG molecular test market has seen substantial growth due to increasing awareness of sexually transmitted infections and advancements in molecular diagnostic technologies. The Food and Drug Administration (FDA) has approved several new, highly sensitive and rapid molecular tests for Chlamydia and Gonorrhea, streamlining the testing process for healthcare providers. The integration of these tests into routine screenings, especially in high-risk populations, is contributing to a decline in transmission rates. Moreover, the U.S. has witnessed a growing demand for at-home testing kits, further driving the market's expansion by making testing more accessible.
  • China: China is experiencing a rapid expansion of the CT-NG molecular test market due to a rising burden of sexually transmitted infections and increasing awareness about their prevention. The Chinese government has been working to improve healthcare infrastructure and access to diagnostics, with a growing emphasis on molecular testing. Innovations in mobile health technologies and the expansion of telemedicine are allowing for greater accessibility of CT-NG tests, particularly in rural areas. Moreover, regulatory bodies are streamlining the approval process for molecular tests, which is likely to further boost market growth in the coming years.
  • Germany: Germany's CT-NG molecular test market is driven by its strong healthcare infrastructure and commitment to preventive medicine. With a well-established healthcare system, Germany has integrated molecular diagnostics widely across hospitals, clinics, and public health programs. The market has benefited from the country's robust public health initiatives aimed at controlling STIs. Additionally, regulatory bodies in Germany have provided a supportive environment for the development and approval of new diagnostic technologies, including PCR-based molecular tests. The increasing availability of point-of-care (POC) testing devices is also contributing to the market's growth by providing quicker and more efficient results.
  • India: India is witnessing significant growth in the CT-NG molecular test market due to increasing healthcare awareness and a growing focus on sexual health. The government's efforts to reduce the incidence of STIs, especially in urban and rural areas, are driving the adoption of molecular testing. With the rapid rise of smartphone-based diagnostics and telemedicine services, molecular tests for Chlamydia and Gonorrhea are becoming more accessible to a wider population. Additionally, the development of affordable and efficient diagnostic solutions is improving the availability of CT-NG molecular tests across India's diverse healthcare systems.
  • Japan: In Japan, the CT-NG molecular test market is driven by high demand for precision diagnostics and advanced healthcare technologies. The country's well-developed healthcare system has facilitated the adoption of molecular testing, particularly in urban hospitals and clinics. With a focus on precision medicine, Japan has seen increased use of PCR-based diagnostics for early detection of Chlamydia and Gonorrhea infections. The Japanese market also benefits from strong regulatory support for molecular diagnostic innovations. The growing focus on preventive healthcare, especially in light of increasing STIs among younger populations, is expected to further drive the adoption of CT-NG molecular tests.

Features of the Global CT-NG Molecular Test Market

  • Market Size Estimates: Ct-ng molecular test market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Ct-ng molecular test market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Ct-ng molecular test market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the CT-NG molecular test market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the CT-NG molecular test market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the CT-NG molecular test market by type (assays & kits, analyzers, and others), application (diagnostic laboratories, hospitals & clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global CT-NG Molecular Test Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Assays & Kits: Trends and Forecast (2019-2031)
  • 4.4 Analyzers: Trends and Forecast (2019-2031)
  • 4.5 Others: Trends and Forecast (2019-2031)

5. Global CT-NG Molecular Test Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Diagnostic Laboratories: Trends and Forecast (2019-2031)
  • 5.4 Hospitals & Clinics: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global CT-NG Molecular Test Market by Region

7. North American CT-NG Molecular Test Market

  • 7.1 Overview
  • 7.4 United States CT-NG Molecular Test Market
  • 7.5 Mexican CT-NG Molecular Test Market
  • 7.6 Canadian CT-NG Molecular Test Market

8. European CT-NG Molecular Test Market

  • 8.1 Overview
  • 8.4 German CT-NG Molecular Test Market
  • 8.5 French CT-NG Molecular Test Market
  • 8.6 Spanish CT-NG Molecular Test Market
  • 8.7 Italian CT-NG Molecular Test Market
  • 8.8 United Kingdom CT-NG Molecular Test Market

9. APAC CT-NG Molecular Test Market

  • 9.1 Overview
  • 9.4 Japanese CT-NG Molecular Test Market
  • 9.5 Indian CT-NG Molecular Test Market
  • 9.6 Chinese CT-NG Molecular Test Market
  • 9.7 South Korean CT-NG Molecular Test Market
  • 9.8 Indonesian CT-NG Molecular Test Market

10. ROW CT-NG Molecular Test Market

  • 10.1 Overview
  • 10.4 Middle Eastern CT-NG Molecular Test Market
  • 10.5 South American CT-NG Molecular Test Market
  • 10.6 African CT-NG Molecular Test Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global CT-NG Molecular Test Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Roche
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Hologic
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Thermo Fisher Scientific
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Abbott
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 PerkinElmer
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Qiagen
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Siemens Healthineers
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Danaher
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 BD
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Bio-Rad
    • Company Overview
    • CT-NG Molecular Test Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global CT-NG Molecular Test Market
  • Figure 2.1: Usage of CT-NG Molecular Test Market
  • Figure 2.2: Classification of the Global CT-NG Molecular Test Market
  • Figure 2.3: Supply Chain of the Global CT-NG Molecular Test Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the CT-NG Molecular Test Market
  • Figure 4.1: Global CT-NG Molecular Test Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global CT-NG Molecular Test Market ($B) by Type
  • Figure 4.3: Forecast for the Global CT-NG Molecular Test Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Assays & Kits in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Analyzers in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Others in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 5.1: Global CT-NG Molecular Test Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global CT-NG Molecular Test Market ($B) by Application
  • Figure 5.3: Forecast for the Global CT-NG Molecular Test Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Diagnostic Laboratories in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Hospitals & Clinics in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global CT-NG Molecular Test Market (2019-2031)
  • Figure 6.1: Trends of the Global CT-NG Molecular Test Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global CT-NG Molecular Test Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American CT-NG Molecular Test Market (2019-2031)
  • Figure 7.2: North American CT-NG Molecular Test Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American CT-NG Molecular Test Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American CT-NG Molecular Test Market ($B) by Type (2025-2031)
  • Figure 7.5: North American CT-NG Molecular Test Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American CT-NG Molecular Test Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American CT-NG Molecular Test Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European CT-NG Molecular Test Market (2019-2031)
  • Figure 8.2: European CT-NG Molecular Test Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European CT-NG Molecular Test Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European CT-NG Molecular Test Market ($B) by Type (2025-2031)
  • Figure 8.5: European CT-NG Molecular Test Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European CT-NG Molecular Test Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European CT-NG Molecular Test Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC CT-NG Molecular Test Market (2019-2031)
  • Figure 9.2: APAC CT-NG Molecular Test Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC CT-NG Molecular Test Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC CT-NG Molecular Test Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC CT-NG Molecular Test Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC CT-NG Molecular Test Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC CT-NG Molecular Test Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW CT-NG Molecular Test Market (2019-2031)
  • Figure 10.2: ROW CT-NG Molecular Test Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW CT-NG Molecular Test Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW CT-NG Molecular Test Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW CT-NG Molecular Test Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW CT-NG Molecular Test Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW CT-NG Molecular Test Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African CT-NG Molecular Test Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global CT-NG Molecular Test Market
  • Figure 11.2: Market Share (%) of Top Players in the Global CT-NG Molecular Test Market (2024)
  • Figure 12.1: Growth Opportunities for the Global CT-NG Molecular Test Market by Type
  • Figure 12.2: Growth Opportunities for the Global CT-NG Molecular Test Market by Application
  • Figure 12.3: Growth Opportunities for the Global CT-NG Molecular Test Market by Region
  • Figure 12.4: Emerging Trends in the Global CT-NG Molecular Test Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the CT-NG Molecular Test Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the CT-NG Molecular Test Market by Region
  • Table 1.3: Global CT-NG Molecular Test Market Parameters and Attributes
  • Table 3.1: Trends of the Global CT-NG Molecular Test Market (2019-2024)
  • Table 3.2: Forecast for the Global CT-NG Molecular Test Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global CT-NG Molecular Test Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 4.4: Trends of Assays & Kits in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 4.5: Forecast for Assays & Kits in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 4.6: Trends of Analyzers in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 4.7: Forecast for Analyzers in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 4.8: Trends of Others in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 4.9: Forecast for Others in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global CT-NG Molecular Test Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 5.4: Trends of Diagnostic Laboratories in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 5.5: Forecast for Diagnostic Laboratories in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 5.6: Trends of Hospitals & Clinics in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 5.7: Forecast for Hospitals & Clinics in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 5.8: Trends of Others in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global CT-NG Molecular Test Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global CT-NG Molecular Test Market (2025-2031)
  • Table 7.1: Trends of the North American CT-NG Molecular Test Market (2019-2024)
  • Table 7.2: Forecast for the North American CT-NG Molecular Test Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American CT-NG Molecular Test Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American CT-NG Molecular Test Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American CT-NG Molecular Test Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American CT-NG Molecular Test Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States CT-NG Molecular Test Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican CT-NG Molecular Test Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian CT-NG Molecular Test Market (2019-2031)
  • Table 8.1: Trends of the European CT-NG Molecular Test Market (2019-2024)
  • Table 8.2: Forecast for the European CT-NG Molecular Test Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European CT-NG Molecular Test Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European CT-NG Molecular Test Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European CT-NG Molecular Test Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European CT-NG Molecular Test Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German CT-NG Molecular Test Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French CT-NG Molecular Test Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish CT-NG Molecular Test Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian CT-NG Molecular Test Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom CT-NG Molecular Test Market (2019-2031)
  • Table 9.1: Trends of the APAC CT-NG Molecular Test Market (2019-2024)
  • Table 9.2: Forecast for the APAC CT-NG Molecular Test Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC CT-NG Molecular Test Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC CT-NG Molecular Test Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC CT-NG Molecular Test Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC CT-NG Molecular Test Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese CT-NG Molecular Test Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian CT-NG Molecular Test Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese CT-NG Molecular Test Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean CT-NG Molecular Test Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian CT-NG Molecular Test Market (2019-2031)
  • Table 10.1: Trends of the ROW CT-NG Molecular Test Market (2019-2024)
  • Table 10.2: Forecast for the ROW CT-NG Molecular Test Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW CT-NG Molecular Test Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW CT-NG Molecular Test Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW CT-NG Molecular Test Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW CT-NG Molecular Test Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern CT-NG Molecular Test Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American CT-NG Molecular Test Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African CT-NG Molecular Test Market (2019-2031)
  • Table 11.1: Product Mapping of CT-NG Molecular Test Suppliers Based on Segments
  • Table 11.2: Operational Integration of CT-NG Molecular Test Manufacturers
  • Table 11.3: Rankings of Suppliers Based on CT-NG Molecular Test Revenue
  • Table 12.1: New Product Launches by Major CT-NG Molecular Test Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global CT-NG Molecular Test Market